Evidence map›Paper›PMID 24822142›Full record

ArticleCase reports in oncological medicine2014

Importance of HER2 Work-Up and Treatment Even in Patients with Poor Performance Status: A Case Report.

Ali Suner, Hakan Buyukhatipoglu, Ozan Balakan, Mehmet Emin Kalender, Turgay Ulas, Alper Sevinc, Celalettin Camci

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncological medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ali SunerDepartment of Medical Oncology, School of Medicine, Gaziantep University, Kilis Yolu Uzeri, 27310 Gaziantep, Turkey.
Hakan BuyukhatipogluDepartment of Medical Oncology, School of Medicine, Gaziantep University, Kilis Yolu Uzeri, 27310 Gaziantep, Turkey.ORCID 0000-0002-9974-1081
Ozan BalakanDepartment of Medical Oncology, School of Medicine, Gaziantep University, Kilis Yolu Uzeri, 27310 Gaziantep, Turkey.
Mehmet Emin KalenderDepartment of Medical Oncology, School of Medicine, Gaziantep University, Kilis Yolu Uzeri, 27310 Gaziantep, Turkey.
Turgay UlasDepatment of Internal Medicine, Harran University School of Medicine, Sanliurfa, Turkey.
Alper SevincDepartment of Medical Oncology, School of Medicine, Gaziantep University, Kilis Yolu Uzeri, 27310 Gaziantep, Turkey.
Celalettin CamciDepartment of Medical Oncology, School of Medicine, Gaziantep University, Kilis Yolu Uzeri, 27310 Gaziantep, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastric cancer is one of most common types of cancers. Metastatic gastric cancer has a poor prognosis and is accepted as incurable at this stage. Treatment of metastatic gastric cancer did not progress substantially until new targeted agents have come out. Recently published ToGA trial showed promising results in HER2 overexpressing metastatic gastric cancer. In this case we present a case with an excellent complete response with anti-HER2 treatment. Most importantly, we wanted to emphasize (1) the importance of early determination of HER2 overexpression, and (2) to draw attention of anti-HER2 agents in the first line treatment even in patients with a poor performance status.

Identifiers

PMID24822142
PMCPMC4009157

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.